Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toludesvenlafaxine SR for long-term functional recovery in working-age adults with major depressive disorder
ChiCTR2600118686Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of toludesvenlafaxine in major depressive disorder (MDD), sponsored by The Second Xiangya Hospital. Primary endpoint: SDS score. Started Feb 2026; status: recruiting.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2600118686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118686.